Becton, Dickinson FQ4 top line up 4%, non-GAAP EPS up 13%

Becton, Dickinson and Company (NYSE:BDX) fiscal Q4 results:

Revenues: $4,584M (+4.1%); BD Medical: $1,366M (+3.3%); BD Life Sciences: $502M (+4.4%); BD Interventional: $693M (+7.3%).

Net income: $112M (+164.7%); EPS: $0.41 (+164.1%); non-GAAP EPS: $3.31 (+13.0%).

Cash flow ops (FY): $3,330M (+16.2%).

Fiscal 2020 guidance: Revenue growth: 4.0 – 4.5%; non-GAAP EPS: $12.50 – 12.65.

https://seekingalpha.com/news/3514334-becton-dickinson-fq4-top-line-4-percent-non-gaap-eps-13-percent